<DOC>
	<DOCNO>NCT00790556</DOCNO>
	<brief_summary>A 2-period crossover study ass safety , tolerability glucose-lowering effect MK8245 .</brief_summary>
	<brief_title>A Study Evaluate Safety , Tolerability , Pharmacokinetics Pharmacodynamics MK8245 ( 8245-004 ) ( COMPLETED )</brief_title>
	<detailed_description>Hypothesis : Multiple dos MK-8245 sufficiently safe well tolerated patient Type 2 diabetes base assessment clinical laboratory adverse experience ( AEs ) , permit continued clinical investigation .</detailed_description>
	<criteria>Subject diagnosis Type 2 Diabetes treat diet exercise alone single oral antihyperglycemic agent Subject willing follow weightmaintaining diet exercise program equivalent begin 4 week receive study drug , throughout study post study visit Subject nonsmoker and/or use nicotinecontaining product least approximately 6 month Subject history stroke , chronic seizure , major neurological disorder Subject history neoplastic disease ( except nonmelanomatous skin carcinoma , carcinoma situ cervix , malignancy successfully treat least 10 year prior screen , malignancy deem highly unlikely recur . ) Subject history Type 1 Diabetes Mellitus and/or history ketoacidosis Subject history contact lens use within approximately previous 6 month Subject diagnose dry eye syndrome Subject use lipidlowering therapy past 3 month ( Subjects stable monotherapy dose statin may include ) Subject major surgery , donate lose 1 unit blood participate another investigational study within 4 week start study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2016</verification_date>
</DOC>